Prospective Registry of Patients With Pancreas Adenocarcinoma Resectable and Borderline
- Conditions
- Pancreas CancerChemotherapy Effect
- Interventions
- Procedure: Neoadyuvant therapy
- Registration Number
- NCT05514171
- Lead Sponsor
- Hospital del Mar
- Brief Summary
Unlike other types of gastrointestinal tumors, there is controversial evidence of the efficacy of neoadjuvant therapy in patients with borderline and resectable adenocarcinoma (ADK) of the pancreas, the objective of this study is to perform a "snapshot" of the usual practice in our setting in terms of neoadjuvant therapy in ADK, both in terms of the different regimens used as well as the results in terms of morbidity, mortality and survival.
Likewise, in a second phase, a prospective registry of patients included in the neoadjuvant regimen for both resectable and borderline ADK diagnosed in Catalonia will be launched, which will provide us with valuable information to try to answer open questions in the context of borderline and resectable ADK treatment.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 300
- resectable or borderline pancreas ADK
- with or without radiotherapy
- any type of approach
- any type of surgery
- locally advanced ADK
- No consent
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Neoadyuvant therapy Neoadyuvant therapy Patients with borderline or resectable ADK subjected to neoadyuvant therapy
- Primary Outcome Measures
Name Time Method Disease free survival Three years follow-up
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Hospital del Mar
🇪🇸Barcelona, Spain